Adynxx

Adynxx Liabilities

The The Liabilities of Adynxx (ADYX) as of Nov 22, 2026 is 1.43 M USD. In the previous year, The Liabilities was 17.27 M USD — a change of -91.74% (lower).

Liabilities

1.43 MUSD

YoY

-91.74%

Last updated:

In 2018, Adynxx's total liabilities amounted to 1.43 M USD, a -91.74% difference from the 17.27 M USD total liabilities in the previous year.

The Adynxx Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2014
7.21 M USD
Jan 1, 2015
37.33 M USD
Jan 1, 2016
22.41 M USD
Jan 1, 2017
17.27 M USD
Jan 1, 2018
1.43 M USD
The Adynxx Liabilities history
YEARLiabilitiesYoY
1.43 MUSD-91.74%
17.27 MUSD-22.92%
22.41 MUSD-39.97%
37.33 MUSD+417.53%
7.21 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adynxx Stock analysis

What does Adynxx do? Adynxx Inc. is a biotechnology company focused on the development of novel, non-opioid-based pain therapies. The company was founded in 2007 in San Francisco, California, and has since pursued ambitious goals in the field of pain treatment. Adynxx has raised over $65 million in investments since its inception and has an experienced team of experts from the pharmaceutical industry, academic researchers, and business professionals. The company's business model is based on offering non-opioid pain therapy based on the blocking of the Kv1.7 protein. Adynxx aims to use this therapy in various areas such as surgery, acute pain management, and chronic pain treatment. The company employs an agile approach to clinical studies, allowing for quick adaptation to new insights and optimization of the effectiveness and safety of pain treatment. Adynxx operates in three areas: surgery, acute pain management, and chronic pain. Each division aims to provide pain patients with an effective alternative to opioid-based pain medications. The product line includes various non-opioid analgesics based on the blocking of the Kv1.7 protein. The flagship product, AYX1, is currently in Phase II clinical trials. It is an injection administered before or during surgery to relieve pain and offers up to 72 hours of pain relief. Another product in development is AYX2, intended for the treatment of chronic pain. Adynxx has the potential to fundamentally change pain treatment and provide a safe alternative to opioid-based pain medications, offering pain patients effective, safe, and sustainable relief and contributing to an improvement in quality of life. Adynxx is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Adynxx's Liabilities

Adynxx's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Adynxx's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Adynxx's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Adynxx's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Adynxx’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Adynxx stock

The Liabilities of Adynxx is 1.43 M USD in 2018.

The Liabilities of Adynxx changed from 17.27 M USD to 1.43 M USD, representing a -91.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Adynxx since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Adynxx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Adynxx

All Key Metrics — Adynxx